Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-10

Clinical Trial Update: Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Biomea Fusion's BMF-219 in Type 1 Diabetes Mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BMF-219 (covalent menin inhibitor)

Snippet

Sponsor: Biomea Fusion Inc. | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: TERMINATED